Harold J Burstein MD PhD and Lisa A Carey MD on Innovations in Triple Neg BC

William M. Sikov, MD, on the CALGB 40603 Trial

William M. Sikov, MD, of Women and Infants Hospital, discusses abstract S4-05, "Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response rates in triple-negative breast cancer after neoadjuvant chemotherapy with or without carboplatin or bevacizumab: CALGB 40603/150709 (Alliance)."

Breast Cancer

Hope S. Rugo, MD

Hope S. Rugo, MD, on the Phase II FIRST Study

Hope S. Rugo, MD, of the University of California, San Francisco, discusses abstract S6-04, “Fulvestrant 500 mg vs anastrozole as first-line treatment for advanced breast cancer: Overall survival from the phase II FIRST study,” presented by John F.R. Robertson, MD.

Breast Cancer

Jack Cuzick, PhD

Jack Cuzick, PhD, on the IBIS-I Trial

Jack Cuzick, PhD, of the Wolfson Institute of Preventive Medicine, discusses abstract S3-07, "16-year long-term follow-up of the IBIS-I breast cancer prevention trial."

Breast Cancer

William J. Gradishar, MD, and Edith A. Perez, MD

William J. Gradishar, MD, and Edith A. Perez, MD, on Immunotherapy and highlights of the Bolero-1 and SOFT Trials

William J. Gradishar, MD, of Northwestern University, and Edith A. Perez of the Mayo Clinic Cancer Center, discuss immunotherapy and the highlights of the BOLERO-1 and SOFT trials.

Breast Cancer

Jame Abraham, MD, FACP

Jame Abraham, MD, FACP, on Immunotherapy in Triple-Negative Breast Cancer

Jame Abraham, MD, FACP, of the Cleveland Clinic, offers his thoughts on abstract S1-09, "A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer," presented by Rita Nanda, MD.

Harold J. Burstein, MD, PhD, and Lisa A. Carey, MD, on Innovations in Triple-Negative Breast Cancer

Related Videos

William M. Sikov, MD, on the CALGB 40603 Trial

Hope S. Rugo, MD, on the Phase II FIRST Study

Jack Cuzick, PhD, on the IBIS-I Trial

William J. Gradishar, MD, and Edith A. Perez, MD, on Immunotherapy and highlights of the Bolero-1 and SOFT Trials

Jame Abraham, MD, FACP, on Immunotherapy in Triple-Negative Breast Cancer

What Constitutes Clinical Expertise in an AI-Enabled Era

American Cancer Society Urges Men to Understand Their Risk for Prostate Cancer

Two Phase III Trials Explore B7-H3–Directed ADCs in Relapsed SCLC

ADC/Immunotherapy Combination Shows Activity in Treatment-Resistant Nasopharyngeal Carcinoma

Long-Term Benefit Seen With Adjuvant Osimertinib in EGFR-Mutated NSCLC